NO20060632L - New compounds and compositions comprising sterols and / or stanols and cholesterol biosynthesis inhibitors and their use in the treatment or prevention of a variety of diseases and conditions - Google Patents
New compounds and compositions comprising sterols and / or stanols and cholesterol biosynthesis inhibitors and their use in the treatment or prevention of a variety of diseases and conditionsInfo
- Publication number
- NO20060632L NO20060632L NO20060632A NO20060632A NO20060632L NO 20060632 L NO20060632 L NO 20060632L NO 20060632 A NO20060632 A NO 20060632A NO 20060632 A NO20060632 A NO 20060632A NO 20060632 L NO20060632 L NO 20060632L
- Authority
- NO
- Norway
- Prior art keywords
- compositions
- stanols
- conditions
- sterols
- diseases
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 4
- 229930182558 Sterol Natural products 0.000 title abstract 3
- 230000015572 biosynthetic process Effects 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 150000003432 sterols Chemical class 0.000 title abstract 3
- 235000003702 sterols Nutrition 0.000 title abstract 3
- 235000012000 cholesterol Nutrition 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Foreliggende oppfinnelse tilveiebringer i et aspekt, nye forbindelser som innbefatter steroler og/eller stanoler og biosynteseinhibitorer, som inkluderer salter av disse forbindelsene og solvater og prodrugs av disse forbindelsene og/eller salter. I et annet aspekt tilveiebringer foreliggende oppfinnelse sammensetninger som innbefatter minst en sterol og/eller stanolester og minst en kolesterolbiosynteseinhibitor. Også tilveiebrakt er fremgangsmåter for behandling eller hindring av et antall sykdonuner, tilstander og forstyrrelser ved å administrere forbindelsene eller sammensetningene tilveiebrakt heri.In one aspect, the present invention provides novel compounds which include sterols and / or stanols and biosynthesis inhibitors, which include salts of these compounds and solvates and prodrugs of these compounds and / or salts. In another aspect, the present invention provides compositions which include at least one sterol and / or stanol ester and at least one cholesterol biosynthesis inhibitor. Also provided are methods for treating or preventing a plurality of disease donors, conditions and disorders by administering the compounds or compositions provided herein.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61545603A | 2003-07-09 | 2003-07-09 | |
| PCT/CA2004/000999 WO2005005453A2 (en) | 2003-07-09 | 2004-07-09 | Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20060632L true NO20060632L (en) | 2006-04-06 |
Family
ID=34062381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20060632A NO20060632L (en) | 2003-07-09 | 2006-02-09 | New compounds and compositions comprising sterols and / or stanols and cholesterol biosynthesis inhibitors and their use in the treatment or prevention of a variety of diseases and conditions |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1644399A2 (en) |
| JP (1) | JP2007525470A (en) |
| KR (1) | KR20060052792A (en) |
| CN (1) | CN1832957A (en) |
| AU (1) | AU2004255285A1 (en) |
| BR (1) | BRPI0412439A (en) |
| CA (1) | CA2531836A1 (en) |
| MX (1) | MXPA06000326A (en) |
| NO (1) | NO20060632L (en) |
| NZ (1) | NZ545087A (en) |
| PL (1) | PL379516A1 (en) |
| RU (1) | RU2006103797A (en) |
| WO (1) | WO2005005453A2 (en) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007283113A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
| KR100886466B1 (en) * | 2006-09-12 | 2009-03-04 | (주)한국씨엔에스팜 | Novel stigmasterol derivatives or pharmaceutically acceptable salts thereof, preparation methods thereof, and compositions for preventing and treating obesity or hyperlipidemia comprising the same |
| DE102007005045B4 (en) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazine derivatives, process for their preparation and their use as medicines |
| EP2025674A1 (en) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
| DE102007054497B3 (en) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Novel crystalline diphenylazetidinone hydrates and process for their preparation |
| EP2310372B1 (en) | 2008-07-09 | 2012-05-23 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| ES2443016T3 (en) | 2009-08-26 | 2014-02-17 | Sanofi | New crystalline hydrates of heteroaromatic fluoroglycosides, pharmaceutical products comprising these compounds, and their use |
| EP2582709B1 (en) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
| EP2766349B1 (en) | 2011-03-08 | 2016-06-01 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683699B1 (en) | 2011-03-08 | 2015-06-24 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683700B1 (en) | 2011-03-08 | 2015-02-18 | Sanofi | Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use |
| US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| EP2683705B1 (en) | 2011-03-08 | 2015-04-22 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| WO2012120057A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9717742B2 (en) | 2012-05-07 | 2017-08-01 | The Regents Of The University Of California | Oxysterol analogue OXY133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis |
| KR20140081339A (en) * | 2012-12-21 | 2014-07-01 | 부경대학교 산학협력단 | Pharmaceutical composition for prevention or treatment of neurodegenerative disease comprising fucosterol |
| JP2016517888A (en) | 2013-05-02 | 2016-06-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Oxysterol bone targeting drug for osteoselective bone formation |
| US9657052B2 (en) | 2014-12-09 | 2017-05-23 | Warsaw Orthopedic, Inc. | Compounds and methods of making sterols using diols |
| CN104434927A (en) * | 2014-12-16 | 2015-03-25 | 吉林农业大学 | Application of bicyclopentanoperhydrophenanthrene malonate B in preparing hypotensive drugs |
| US10632230B2 (en) | 2015-07-10 | 2020-04-28 | Warsaw Orthopedic, Inc. | Implants having a high drug load of an oxysterol and methods of use |
| US9987289B2 (en) | 2015-07-10 | 2018-06-05 | Warsaw Orthopedic, Inc. | Slow release oxysterols and methods of use |
| US9877836B2 (en) | 2015-07-10 | 2018-01-30 | Warsaw Orthopedic, Inc. | Compression resistant implants including an oxysterol and methods of use |
| US12171909B2 (en) | 2015-07-10 | 2024-12-24 | Warsaw Orthopedic, Inc. | Implants having a drug load of an oxysterol and methods of use |
| CN105087609B (en) * | 2015-08-19 | 2018-10-23 | 四川大学 | A kind of recombinant slow virus and its purposes in the drug for preparing treatment cocaine habituation |
| CN105055404B (en) * | 2015-08-19 | 2017-07-18 | 四川大学 | Purposes of the HMGCS2 inhibitor in the medicine for preparing treatment cocaine habituation |
| US10688222B2 (en) | 2016-11-21 | 2020-06-23 | Warsaw Orthopedic, Inc. | Lyophilized moldable implants containing an oxysterol |
| US11384114B2 (en) | 2016-12-09 | 2022-07-12 | Warsaw Orthopedic, Inc. | Polymorphic forms of an oxysterol and methods of making them |
| US10434106B2 (en) * | 2017-05-19 | 2019-10-08 | Warsaw Orthopedic, Inc. | Oxysterol-statin compounds for bone growth |
| US11464888B2 (en) | 2017-06-12 | 2022-10-11 | Warsaw Orthopedic, Inc. | Moldable formulations containing an oxysterol in an acellular tissue matrix |
| KR102139994B1 (en) * | 2017-10-25 | 2020-07-31 | 대구대학교 산학협력단 | Pharmaceutical composition for use in preventing or treating osteoporosis containing stigmasterol as an active ingredient |
| CN113143935B (en) * | 2021-02-01 | 2022-10-11 | 广东药科大学 | Application of stigmasterol in the preparation of drugs for improving cardiac hypertrophy |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5216015A (en) * | 1991-02-05 | 1993-06-01 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compounds having hypocholesterolemic properties |
| EP1420026A3 (en) * | 1999-06-23 | 2004-12-15 | Forbes Medi-Tech Inc. | Use of conjugates of phytosterol or phytostanol with ascorbic acid in treating or preventing cardiovascular disease, and compositions thereof |
-
2004
- 2004-07-09 RU RU2006103797/04A patent/RU2006103797A/en not_active Application Discontinuation
- 2004-07-09 KR KR1020067000470A patent/KR20060052792A/en not_active Ceased
- 2004-07-09 NZ NZ545087A patent/NZ545087A/en unknown
- 2004-07-09 EP EP04737936A patent/EP1644399A2/en not_active Withdrawn
- 2004-07-09 AU AU2004255285A patent/AU2004255285A1/en not_active Abandoned
- 2004-07-09 WO PCT/CA2004/000999 patent/WO2005005453A2/en not_active Ceased
- 2004-07-09 MX MXPA06000326A patent/MXPA06000326A/en unknown
- 2004-07-09 CA CA002531836A patent/CA2531836A1/en not_active Abandoned
- 2004-07-09 PL PL379516A patent/PL379516A1/en unknown
- 2004-07-09 CN CNA2004800228667A patent/CN1832957A/en active Pending
- 2004-07-09 JP JP2006517922A patent/JP2007525470A/en not_active Withdrawn
- 2004-07-09 BR BRPI0412439-1A patent/BRPI0412439A/en not_active IP Right Cessation
-
2006
- 2006-02-09 NO NO20060632A patent/NO20060632L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1832957A (en) | 2006-09-13 |
| CA2531836A1 (en) | 2005-01-20 |
| KR20060052792A (en) | 2006-05-19 |
| NZ545087A (en) | 2009-10-30 |
| PL379516A1 (en) | 2006-10-02 |
| WO2005005453A2 (en) | 2005-01-20 |
| WO2005005453A3 (en) | 2005-06-09 |
| MXPA06000326A (en) | 2006-03-30 |
| JP2007525470A (en) | 2007-09-06 |
| BRPI0412439A (en) | 2006-09-05 |
| EP1644399A2 (en) | 2006-04-12 |
| RU2006103797A (en) | 2006-07-27 |
| AU2004255285A1 (en) | 2005-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20060632L (en) | New compounds and compositions comprising sterols and / or stanols and cholesterol biosynthesis inhibitors and their use in the treatment or prevention of a variety of diseases and conditions | |
| TNSN08153A1 (en) | Anti-hypercholesterolemic compounds | |
| WO2006121861A3 (en) | Biphenylazetidinone cholesterol absorption inhibitors | |
| NO20065847L (en) | Diphenylimidazopyrimidines and imidazolamines as inhibitors of B-secretase | |
| NO20050016L (en) | Diphenyllazetidinone derivatives for the treatment of lipid metabolism disorders | |
| NO20070247L (en) | Amino-5,5-diphenylimidazolone derivatives for inhibition of beta-secretase | |
| NO20074647L (en) | 3,4 dihydro-1H-isoquinoline-2-carboxylic acid 5-ammopyridin-2-yl esters | |
| WO2008073452A8 (en) | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors | |
| NO20085323L (en) | Melted, tricyclic sulfonamide inhibitors of gamma secretase | |
| EP2332527A3 (en) | Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases | |
| NO20061454L (en) | Compounds having CRTH2 antagonist activity | |
| NO20070876L (en) | Apolipoprotein A1 mimetics and uses thereof. | |
| Fortunati et al. | Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells | |
| NO20084489L (en) | Azolopyrimidines as inhibitors of cannabinoid 1 activity | |
| PL369108A1 (en) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
| WO2007027855A3 (en) | Raf inhibitor compounds and methods of use thereof | |
| NO20055314L (en) | 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and treatment of disease | |
| BRPI0206641B8 (en) | use of a sterol absorption inhibitor | |
| WO2006138163A3 (en) | Anti-hypercholesterolemic compounds | |
| NO20076195L (en) | New 2-azetidinone derivatives for the treatment of hyperlipidemic diseases | |
| NO20076137L (en) | New 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidemia | |
| TW200744638A (en) | Combinations of bile acid sequestrant(s) and sterol absorption inhibitors and treatments for vascular indications | |
| NO20076197L (en) | New 2-azetidinone derivatives useful in the treatment of hyperlipidemic conditions | |
| WO2004043456A8 (en) | Cholesterol absorption inhibitors for the treatment of demyelination | |
| NO20062591L (en) | Diphenyllazetidinone derivatives with cholesterol absorption inhibitory activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |